Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $10.3375, but opened at $9.74. Bavarian Nordic shares last traded at $9.74, with a volume of 273 shares changing hands.
Bavarian Nordic Price Performance
The firm’s 50 day simple moving average is $10.19 and its two-hundred day simple moving average is $10.88. The firm has a market capitalization of $2.32 billion, a P/E ratio of 6.28 and a beta of 1.34.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.
See Also
- Five stocks we like better than Bavarian Nordic
- CSE: ALEN.U is targeting a fast-growing digital wellness market
- New Copper-Rich “Kraken” Zone Discovered
- 1,500 Banks Just Handed the Fed Your Bank Account
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
